INIS
inhibition
100%
phosphodiesterases
87%
injuries
72%
cyclic adenosine monophosphate
57%
spinal cord
53%
central nervous system
47%
levels
25%
mice
25%
reviews
25%
precursor
25%
cell differentiation
25%
losses
23%
myelin
16%
neurons
16%
repair
14%
nervous system diseases
13%
humans
13%
inflammation
12%
pathology
9%
side effects
9%
enzymes
9%
data
8%
death
8%
complement
8%
damage
8%
recovery
6%
patients
6%
viability
6%
luminescence
6%
quality of life
6%
Medicine and Dentistry
Phosphodiesterase
81%
Cyclic AMP
57%
Spinal Cord Injury
53%
Central Nervous System
48%
Cell Differentiation
25%
Oligodendrocyte
25%
Oligodendrocyte Precursor Cell
25%
Phosphodiesterase IV Inhibitor
17%
Microglia
16%
Myelin
16%
Alzheimer's Disease
15%
Synapse
12%
Multiple Sclerosis
11%
Second Messenger
10%
Hydrolase
10%
Side Effect
10%
Neuroinflammation
10%
Central Nervous System Disease
9%
Drive
8%
Demyelination
8%
Neurodegeneration
8%
Demyelinating Disorder
8%
Remyelination
8%
Complement Component C1q
8%
Injury
7%
Roflumilast
7%
Emetic Agent
7%
Programmed Cell Death
7%
Induced Pluripotent Stem Cell
7%
Nerve Cell Differentiation
7%
Keyphrases
Phosphodiesterase-4 (PDE4)
84%
Cyclic Adenosine Monophosphate (cAMP)
57%
Spinal Cord Injury
53%
Central Nervous System
31%
PDE4 Inhibition
25%
APPswe
25%
Mental Resilience
25%
APPswePS1dE9
25%
PDE4 Inhibitor
15%
Alzheimer's Disease
10%
Phosphodiesterase
9%
Novel Therapeutics
9%
Promising Strategies
9%
Hydrolytic Enzymes
9%
Neuroinflammation
9%
Second Messenger
9%
Nervous System Diseases
9%
Axonal Neurodegeneration
8%
Microglial Activation
7%
Microglia
7%
Primary Injury
6%
Neurospheroids
6%
Regeneration
6%
Clinical Application
6%
PDE4B Inhibitors
6%
Therapeutic Agents
6%
Regenerative Repair
6%
Apoptosis
6%
Human iPSC
6%
Patient Well-being
6%